Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement

Annals of Pharmacotherapy

Volumn 36, Issue 4, 2002, Pages 702-706

  Rathbun, R Chris ^a   Rossi, Deanna R ^a   Nazario, Mitchell ^a   Edouard, Bruno ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

HIV; Pharmacokinetics; Protease inhibitors; Ritonavir

Indexed keywords

AMOROLFINE; INDINAVIR; LOPINAVIR; NELFINAVIR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PROTEINASE INHIBITION; TREATMENT OUTCOME;

EID: 0036204259     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1A202     Document Type: Article

References (31)

1. Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease
2. Discontinuation rates for protease inhibitor regimens containing ritonavir 600 mg versus ritonavir 400 mg plus saquinavir 400 mg
3. Dual protease inhibitor therapy in HIV-infected patients: Pharmacologic rationale and clinical benefit
4. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals
5. A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: Pharmacokinetics, safety, efficacy
6. A randomized study comparing continued indinavir (800 mg tid) versus switching to indinavir/ritonavir (800/100 mg bid) in HIV patients having achieved viral load suppression with indinavir plus 2 nucleoside analogues: The BID Efficacy and Safety Trial (BEST)
7. Indinavir/ritonavir vs. indinavir in combination with AZT/3TC for treatment of HIV in nucleoside-experienced patients: A randomized, open-label trial
8. Experience of indinavir (IDV) plus ritonavir (RTV) as part of a salvage regimen in extensively pretreated HIV patients in clinical practice
9. Increased indinavir levels using twice daily ritonavir/indinavir at 100/800 mg improves virologic response even after multiple failure
10. Tolerance and efficacy of indinavir 800 mg plus ritonavir 100 mg bid in addition to nucleoside analogues in HIV infected patients
11. Efficacy of indinavir (IDV)/ritonavir(RTV)-based regimens (IRBR) among patients with prior protease inhibitor failure
12. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy
13. Dose-finding study of once-daily indinavir/ritonavir plus zidovudine and lamivudine in HIV-infected patients
14. Dose-finding study of a once-daily indinavir/ritonavir regimen
15. Preliminary results from indinavir (IDV) and ritonavir (RTV) in a once-daily regimen (Merck 103/104)
16. The effect of ritonavir on increases in saquinavir plasma concentration is independent of ritonavir dosage: Combined analysis of 120 subjects
17. Safety and pharmacokinetics of once-daily regimens of soft-gel saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults
18. Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: A pharmacokinetic pilot study
19. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers
20. Therapeutic drug monitoring of amprenavir combined with ritonavir as salvage therapy in HIV-1 infected patients
21. The combination of ritonavir and amprenavir in salvage regimens overcomes clinically multiple-drug resistant HIV
22. Amprenavir (APV) 600 mg/ritonavir (RTV) 100 mg BID or APV 1200 mg/RTV 200 mg QD given in combination with abacavir (ABC) and lamivudine (3TC) maintains efficacy in ART-naïve HIV-1-infected adults over 12 weeks (AV20001)
23. The influence of ritonavir on the pharmacokinetics of nelfinavir 1250 mg BID
24. Pharmacokinetics (PK) of nelfinavir (NFV) after once daily dosing in combination with mini-doses of ritonavir (RTV) in healthy subjects
25. Interactions among drugs for HIV and opportunistic infections
26. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naïve adults with HIV-1 infection: 48-Week results
27. Two year follow-up of ABT-378/ritonavir (ABT-378/r) in antiretroviral naïve HIV+ patients
28. Efficacy of ABT-378 vs. nelfinavir (NFV) in antiretroviral (ARV)-naïve subjects: Results of a phase III blinded randomized clinical trial